Idorsia Ltd (IDRSF) reports strong commercial momentum and strategic financing moves despite ongoing operational losses.

Idorsia’s analyst story has shifted again, with a new CHF 5 price target sitting alongside an unchanged fair value estimate of CHF 4.5. This reset reflects a mix of confidence in the company’s assets and concern around higher operating expenses and execution risks, as highlighted in recent analyst commentary. As you read on, you will see how these changing targets shape the evolving narrative and what to watch if you are tracking the stock. Stay updated as the Fair Value for Idorsia shifts by...

Idorsia’s fair value price target has been revised from CHF 4.83 to CHF 4.50, a modest reset that keeps the focus on how the story is evolving rather than rewriting it entirely. The move reflects a mixed analyst narrative, with some highlighting long term potential that still supports price targets around CHF 5, while others point to execution risks and spending as reasons for caution. Read on to see what is driving these views and how to follow the next steps in Idorsia’s evolving investment...

Following local regulatory approval, Idorsia will supply finished product to Pharmalink at a pre-determined price.

How Idorsia’s Recent Performance Frames the Investment Question Idorsia (SWX:IDIA) has caught investor attention after a mixed performance, with a 1 year total return above 200% contrasted by weaker results over the past 3 years and 5 years. Over the past month, the stock has recorded a 5% decline, alongside a 10% decline over the past 3 months and a 13% decline year to date, creating a contrasting backdrop to its recent annual return. See our latest analysis for Idorsia. At a share price of...

Idorsia Ltd (IDRSF) reports significant sales growth and strategic advancements, despite ongoing financial challenges and market uncertainties.

In late January 2026, Idorsia announced an exclusive license and supply agreement with EMS S.A. to register and commercialize its insomnia drug QUVIVIQ (daridorexant) across Latin America, including milestone payments of US$20,000,000, supply revenues, and double-digit royalties in Brazil and Mexico. Alongside this expansion for QUVIVIQ, fresh long-term data for Idorsia’s Fabry disease candidate lucerastat have drawn attention to the company’s broader late-stage pipeline. We will now examine...

Idorsia (SWX:IDIA) has been catching investor attention after its recent share performance and ongoing clinical development work, prompting fresh questions about how its current valuation lines up with its drug pipeline and financial profile. See our latest analysis for Idorsia. At a share price of CHF 3.71, Idorsia’s recent 7 day share price return of 12.81% decline and 90 day share price return of 19.35% decline contrast sharply with its very large 1 year total shareholder return of about...

Idorsia’s stock narrative has shifted following a recent price target update, with the fair value estimate holding steady at CHF 2.00. A slight decrease in the company’s discount rate suggests growing analyst confidence. At the same time, stable revenue projections have supported optimism around these changes. Stay tuned to discover how you can monitor future adjustments to Idorsia’s evolving investment story as new factors emerge. Analyst Price Targets don't always capture the full story...